Ascendis Pharma (ASND) director details shares, warrants and RSUs
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Ascendis Pharma A/S director Jan Moller Mikkelsen filed an initial ownership report showing a mix of ordinary shares, warrants and restricted stock units. He directly holds 384,933 ordinary shares and indirectly holds 68,470 ordinary shares through Cadenza Partners.
The filing lists several fully vested, currently exercisable warrant series over ordinary shares with exercise prices ranging from 37.18 to 176.28 and expirations from December 2027 through December 2031. It also discloses three restricted stock unit awards over ordinary shares (delivered as ADSs) covering 15,825, 23,834 and 28,945 underlying shares, which vest beginning on March 1, 2027.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
MIKKELSEN JAN MOLLER
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Warrants — 200,000 shares (Direct);
Restricted Stock Units — 15,825 shares (Direct);
Ordinary Shares — 384,933 shares (Direct);
Ordinary Shares — 68,470 shares (Indirect, By Cadenza Partners)
Footnotes (1)
- Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share. The warrants are fully vested and currently exercisable. The restricted stock units vest on March 1, 2027 and have no expiration date. Each restricted stock unit represents a contingent right to receive one ADS. The restricted stock units vest in two equal annual installments beginning on March 1, 2027. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.
FAQ
What did Ascendis Pharma (ASND) disclose in Jan Moller Mikkelsen’s Form 3?
Ascendis Pharma reported director Jan Moller Mikkelsen’s initial ownership, including ordinary shares, warrants and restricted stock units. The filing establishes his baseline equity exposure as a board member, combining direct and indirect holdings plus multiple derivative awards over Ascendis Pharma ordinary shares and ADSs.
What restricted stock units does Jan Moller Mikkelsen hold in Ascendis Pharma?
The filing shows three restricted stock unit grants over 15,825, 23,834 and 28,945 underlying Ascendis Pharma ordinary shares. These RSUs vest beginning March 1, 2027, in annual installments, and each unit represents a contingent right to receive one American Depositary Share.